After observing decreased expression of both CD19 and CD22 in our model of adaptive resistance, we wanted to examine their expression in pediatric patients with ALL who had received one of several CD19-targeted therapies and had relapsed with CD19–/dim disease, and who were then screened for enrollment in or received treatment in a NCI clinical trial. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.